New research reveals that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who end conventional lifestyle programs.
Findings released in a prominent health publication shows that while obese people frequently drop a large proportion of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Users buying such treatments need to be informed of the potential of rapid weight regain when the medication ends," warns researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment weight within about 18 months.
Comparing Treatments
The analysis, which looked at 37 of studies involving thousands of participants, compared the effects of these new drugs with conventional dieting.
Scientists emphasize that people who lose weight through dieting typically experience a less rapid creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Experts suggest the mechanism of the drugs accounts for the heightened weight return.
These medications copy a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 levels far above than normal could lead to the body to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Condition?
The NHS recommend the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of weight regain, the therapy might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who say that the findings "emphasize the chronic character of excess weight," akin to managing conditions like diabetes.
Patient Testimonies
People who have stopped the medication describe a intense resurgence of cravings.
"It was like something that goes on and you become extremely hungry," said one woman.
The struggle is worsened if patients have not developed lasting dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that millions of adults in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is more common among women than men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Finally, experts emphasize that while these medications are powerful tools for shedding pounds, they are not a magic fix and long-term success hinges on combined behavioural support.
